PROSTest

DIAGNOSTIC_TEST3 trials

Sponsors

Wren Laboratories LLC, Washington University School of Medicine

Conditions

Androgen Deprivation TherapyChemotherapyMetastatic Prostate CancerPSAProstate BiopsyProstate CancerProstate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)

Phase 2

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Not yet recruitingNCT07593079

Washington University School of MedicineMetastatic Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic +2

Start: 2026-10-31End: 2028-01-31Target: 20Updated: 2026-09-11

Unknown Phase

RegisterPROS - A Registry for Prostate Cancers

Enrolling by invitationNCT06872619

Wren Laboratories LLCAndrogen Deprivation Therapy, Chemotherapy, Prostate Biopsy +4

Start: 2020-01-15End: 2030-12-15Target: 1000Updated: 2026-08-21

A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth

RecruitingNCT07454603

Wren Laboratories LLCProstate Cancer, Prostate Cancer (Diagnosis), Urology

Start: 2026-04-15End: 2027-06-01Target: 1500Updated: 2026-08-21

Related Papers

Early changes in PROSTest, a blood-based mRNA assay, as a predictor of outcomes of <sup>177</sup> LuPSMA radioligand therapy and chemotherapy in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2026-05-28

Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer

MDPI (MDPI AG)2026-03-08